Edwards Lifesciences Corp (EW) — 分析摘要
Edwards Lifesciences Corp（EW）的市值为52.85十亿美元，最近一年的营收同比增长了+11.5%。净利润率为17.7%。当前市盈率为48.2倍。
核心要点
- 营收同比变化+11.5%
- 净利润率17.7%
- 市盈率48.2倍
与ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES板块的其他公司相比，EW的营收增长为+11.5%，市盈率为48.2倍。
Edwards Lifesciences Corp (EW)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
行业
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
员工人数
16,000
总部
IRVINE, CA
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。